Vera Therapeutics Stock (NASDAQ:VERA)


ForecastChart

Previous Close

$30.50

52W Range

$18.53 - $51.61

50D Avg

$24.02

200D Avg

$26.60

Market Cap

$1.96B

Avg Vol (3M)

$1.50M

Beta

1.23

Div Yield

-

VERA Company Profile


Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

152

IPO Date

May 14, 2021

Website

VERA Performance


Peer Comparison


TickerCompany
VRCAVerrica Pharmaceuticals Inc.
TRMLTourmaline Bio, Inc.
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks